Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency

M. Pane, S. Messina, G. Vasco, A. R. Foley, L. Morandi, E. Pegoraro, T. Mongini, A. D'Amico, F. Bianco, M. E. Lombardo, R. Scalise, C. Bruno, A. Berardinelli, A. Pini, I. Moroni, M. Mora, A. Toscano, M. Moggio, G. Comi, F. M. SantorelliE. Bertini, F. Muntoni, E. Mercuri

Research output: Contribution to journalArticlepeer-review


The aim of this retrospective study was to assess respiratory and cardiac function in a large cohort of patients with congenital muscular dystrophies (CMD) with reduced glycosylation of alphadystroglycan (α-DG). Thirteen of the 115 patients included in the study died between the age of 1. month and 20. years. The age at last follow up of the surviving 102 ranged between 1. year and 68. years (median: 9.3. years). Cardiac involvement was found in 7 of the 115 (6%), 5 with dilated cardiomyopathy, 1 cardiac conductions defects and 1 mitral regurgitation. Respiratory function was impaired in 14 (12%). Ten of the 14 required non invasive nocturnal respiratory support, while the other four required invasive ventilation. Cardiac or respiratory involvement was found in patients with mutations in . FKRP, . POMT1, . POMT2. All of the patients in whom mutation in POMGnT1 were identified had normal cardiac and respiratory function.

Original languageEnglish
Pages (from-to)685-689
Number of pages5
JournalNeuromuscular Disorders
Issue number8
Publication statusPublished - Aug 2012


  • Alpha dystroglycan
  • Congenital muscular dystrophy
  • Heart
  • Respiratory

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology


Dive into the research topics of 'Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency'. Together they form a unique fingerprint.

Cite this